News stories about Oncobiologics (NYSE:ONS) have been trending somewhat positive on Sunday, according to Accern. The research firm identifies positive and negative news coverage by analyzing more than 20 million blog and news sources. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. Oncobiologics earned a media sentiment score of 0.10 on Accern’s scale. Accern also assigned media stories about the company an impact score of 46.6686362181261 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the company’s share price in the near future.
Separately, Zacks Investment Research lowered Oncobiologics from a “buy” rating to a “hold” rating in a research report on Tuesday, July 18th.
Oncobiologics (NYSE:ONS) opened at 1.44 on Friday. The company’s 50-day moving average price is $1.51 and its 200 day moving average price is $1.51. Oncobiologics has a 52-week low of $0.95 and a 52-week high of $4.40. The firm’s market capitalization is $35.53 million.
ILLEGAL ACTIVITY WARNING: This news story was first reported by Transcript Daily and is owned by of Transcript Daily. If you are reading this news story on another website, it was stolen and reposted in violation of international trademark & copyright laws. The original version of this news story can be read at https://transcriptdaily.com/2017/10/08/oncobiologics-ons-receives-coverage-optimism-score-of-0-10.html.
Oncobiologics, Inc is a clinical-stage biopharmaceutical company. The Company is focused on identifying, developing, manufacturing and commercializing biosimilar therapeutics. It is focused on monoclonal antibodies (mAbs) in the disease areas of immunology and oncology. The Company offers BioSymphony Platform.
Receive News & Ratings for Oncobiologics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oncobiologics Inc and related companies with MarketBeat.com's FREE daily email newsletter.